<DOC>
	<DOCNO>NCT00963235</DOCNO>
	<brief_summary>The study evaluate safety , tolerability immunogenicity 13-valent pneumococcal conjugate vaccine ( 13vPnC ) HIV-infected subject 18 year age old previously immunize least one dose 23-valent pneumococcal polysaccharide vaccine ( 23vPS ) . All subject receive 3 dos 13vPnC , study vaccine dose give approximately 6 month apart .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity 13vPnC HIV-Infected Subjects Aged 18 Older Who Were Previously Immunized With 23vPS</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject age 18 year old time enrollment . All female male subject biologically capable child must agree commit use reliable method birth control signing inform consent form ( ICF ) 3 month last dose investigational product . Documented vaccination 1 dose 23vPS least 6 month study enrollment . CD4+ Tcell count &gt; = 200 cells/µ , obtain recent 2 occasion within 6 month first investigational product vaccination . HIVinfected subject viral load &lt; 50,000 copies/mL , obtain recent 2 occasion within 6 month first investigational product vaccination . Subject receive stable dose HAART least 6 week prior first investigational product vaccination , currently receive antiretroviral therapy . Subject expect available entire study period ( approximately 18 month ) contact telephone . Subject must able complete electronic diary ( ediary ) complete relevant study procedure study participation . Subject deem eligible study basis medical history , physical examination , clinical judgment . ( Note : Subjects preexist stable disease , define disease require significant change therapy hospitalization worsen disease 6 week investigational product vaccination , eligible . ) Subjects active AIDS relate illness , include opportunistic infection malignancy . Evidence current illicit substance and/or alcohol abuse , investigator 's opinion , precludes subject participate study interferes evaluation study objectives.. Receipt license experimental pneumococcal conjugate vaccine prior enrollment . Contraindication vaccination pneumococcal conjugate vaccine . Previous anaphylactic reaction vaccine vaccinerelated component . History cultureproven invasive disease cause Streptococcus pneumoniae within last year . Current anticoagulant therapy history bleed diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . ( Note : Use antiplatelet drug , aspirin clopidogrel , permit . ) Pregnant breastfeed woman , define history positive human chorionic gonadotropin ( hCG ) urine test . All woman childbearing potential must urine pregnancy test . History active hepatitis elevation pretreatment aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) value &gt; 5 time upper limit normal within last 6 month . Serious chronic disorder disorder , investigator 's opinion , precludes subject participate study interferes evaluation study objective . ( Note : Serious chronic disorder include metastatic malignancy , severe chronic obstructive pulmonary disease require supplemental oxygen , endstage renal disease without dialysis , clinically unstable cardiac disease ) . Any major illness/condition , investigator 's judgment , substantially increase risk associate subject 's participation completion , study , could preclude evaluation subject 's response . History splenectomy . Receipt blood product , include immunoglobulin , within 42 day investigational product vaccination last blood draw study ( approximately 13 month first investigational product vaccination ) . Evidence dementia severe cognitive impairment . Subject , opinion investigator , unable receive vaccination deltoid muscle either arm insufficient muscle mass . Participation another study use investigational product 28 day study enrollment blood draw visit 6 . Between blood draw visit 6 6 month followup telephone call ( visit 7 ) , use investigational product must discuss Medical Monitor . ( Note : Participation purely observational study acceptable . ) Residence nursing home , longterm care facility , institution requirement semiskilled nursing care . An ambulatory resident retirement home village eligible trial . Subject direct relative ( child , grandchild , parent , grandparent ) study personnel , study personnel . Temporary Delay Criteria : Current febrile illness ( oral temperature =38.0°C [ 100.4°F ] ) acute illness within 48 hour study vaccine administration . Currently receive antibiotic therapy , complete course antibiotic therapy within 10 day study vaccine administration . Receipt novel influenza A ( H1N1 ) vaccine within 14 day investigational product vaccination ( seasonal influenza vaccine give time discretion investigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>vaccine</keyword>
	<keyword>13-valent pneumococcal conjugate vaccine</keyword>
	<keyword>human immunodeficiency virus</keyword>
</DOC>